Drug · Other

Asparaginase

CI-DRUG-00000082Explore in graph →NCIt C286 CHEMBL2108989 CIViC Approved

Regulatory

Approvals (3)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory3 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as ERWINASE (DIN 02237815) under ATC L01XX02 ASPARAGINASE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 9, 2021	Jul 1, 2009	health-canada-dpd
CA Health Canada	—	Marketed in Canada as KIDROLASE (DIN 01926438) under ATC L01XX02 ASPARAGINASE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 7, 2021	Dec 31, 1974	health-canada-dpd
EU EMA	Acute Lymphoblastic Leukemia	Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.	approved	Jan 14, 2016

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 8 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	11	4	43	111	3	CA, EU	Jan 14, 2016	1990-01
Leukemia	Approved	Phase 4	8	3	37	91	1	EU	Jan 14, 2016	1990-01
Non-Hodgkin Lymphoma	Phase4	Phase 4	1	0	2	12	0	—	—	1993-03
Malignant Nasopharyngeal Neoplasm	Phase3	Phase 3	1	0	1	2	0	—

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PRPS1 A190T1
Asparaginase + Cytarabine

Clinical trials

Trials with this intervention (112)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 101–112 of 112 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00018954	Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma	completed	Phase 2	—	National Institutes of Health Clinical Center (CC)NIH	3	Feb 20, 2012	clinicaltrials
NCT00854425	L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma	completed

Molecule

Record

Kind: Other
Mechanism: Asparagine hydrolytic enzyme
Aliases: ASP-1, Asparaginase, Asparaginase-E.Coli, Asparaginase II, Colaspase, E. coli asparaginase, E. coli l-asparaginase, Elspar, ERWINASE, Escherichia coli l-asparaginase, Kidrolase, KIDROLASE, L-Asnase, L-ASP, Laspar, L-asparaginase, L-Asparaginase, L-Asparagine Amidohydrolase, Lcf-ASP, Leucogen, Leunase, MK-965, NSC-109229, Paronal, Re-82-TAD-15, Serasa, Spectrila

Data updated 11 hours agoSource updated unknown

Identifiers

Codes (6)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XX02	ASPARAGINASE
DIN (Health Canada)	01926438	KIDROLASE
DIN (Health Canada)	02237815